Recombinant human activated factor VII (rhFVIIa) has been used successfully to treat hemophilic patients with neutralizing antibodies to FVIII or FIX. High doses of FVIIa are known to be effective in opposing bleeding in hemophilia B mice and in a mouse model of antibody-induced hemophilia A. The therapeutic indications for human plasma-derived coagulation factor VII (pdFVII) include the prophylaxis and treatment of bleeding disorders in isolated congenital or acquired factor VII deficiency. These preparations are considered to be ineffective in hemophilia A in the presence of inhibitors as they do not contain activated factor VII and therefore cannot be used in haemophiliac patients with inhibitors.


Here, we investigated the potential use of pdFVII to induce hemostasis in a mouse model of congenital hemophilia A with high-titer inhibitors and antibody-induced hemophilia A in wild-type mice.


F8 KO mice were given 2 IU recombinant human FVIII intravenously weekly for 4 weeks. All mice that developed high-titer inhibitors (>5 BU/ml) were selected to be used in tail transection experiments. Additionally, a model of antibody-induced hemophilia was used by injecting C57BL/6 wild-type mice with 2 doses of murine plasma containing high-titer inhibitors. Mice were anesthetized and tails transected at a cross-sectional diameter of 1.5 mm; the tail was immediately placed in thermostated saline, and the duration of active bleeding was recorded. Bleeding was monitored for 10 minutes. Blood loss was determined by measuring the amount of released haemoglobin in the saline. Mice were pre-treated 15 minutes before haemostatic challenge with a single i.v. injection of saline, rhFVIIa (4 mg/kg) or pdFVII (500 IU/kg).


Administration of both rhFVIIa and pdFVII corrected the bleeding tendency in both animal models. In particular, pdFVII and rFVIIa treatments caused a marked reduction in the mean bleeding index score of hemophilia A mice with inhibitors in comparison to mice treated with vehicle only (vehicle, mean=5750, s.e.m.= 438; pdFVII, mean=1301, s.e.m.= 819; rFVIIa, mean=1101, s.e.m.=565; P < 0.001 for pdFVII vs vechicle and rFVIIa vs vehicle comparisons, NS for rFVIIa vs pdFVII; ANOVA followed by Bonferroni's multiple comparison test). Comparable results were obtained in the antibody-induced hemophilia model. No statistically significant differences were observed between groups treated with rFVIIa or pdFVII in both models.


Our results provide evidence that pharmacological doses of both rFVIIa and pdFVII are effective in promoting hemostasis in animal models of congenital hemophilia A with inhibitors and antibody-induced hemophilia A in wild-type mice.


No relevant conflicts of interest to declare.

Author notes


Asterisk with author names denotes non-ASH members.